Ipsen has opened its new UK headquarters in Paddington, London. The site, which will serve as one of Ipsen’s three global hubs, will house 300 employees.
It is located at the heart of a growing life sciences community in Paddington, where several other pharmaceutical and technology companies as well as Imperial College London are based.
David Loew, Ipsen CEO, and Ioana Parsons, General Manager of Ipsen UK and Ireland, welcomed Rosalind Campion, Director of the Office for Life Sciences, Dr. Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, and other key stakeholders from the local Paddington area to officially launch the new UK global hub.
David Loew, Chief Executive Officer, Ipsen, said: “Moving our teams into the new global hub in central London builds on 40 years of heritage, marking a new chapter for Ipsen in the UK. Our presence in Paddington further reinforces our continued commitment to the UK, putting us in closer proximity to many key stakeholders.
“Along with our centre of R&D and manufacturing excellence in Wrexham, the new hub will ensure we continue to deliver on our commitment to bringing innovative medicines to people living with high unmet medical needs.”
Rosalind Campion, Director of the Office for Life Sciences, said: “The UK is home to a thriving life sciences industry. Companies like Ipsen who are highly committed to investing in the UK play a pivotal role in realising our ambitions for this sector. It was a pleasure to officially open Ipsen’s new U.K. site today, and to see them bolstering the growing life sciences community here in Paddington.”
Ipsen employs more than 1,000 people in the UK and Ireland, including more than 500 employees based at a dedicated manufacturing site, housed in Wrexham, Wales. With a bench-to-bedside approach, colleagues at Ipsen Paddington include those working in research and development, alongside medical and commercial colleagues, covering both UK and global roles.
